Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: In a letter, 44 firms, including Allianz, Handelsbanken, Aberdeen Investment and Aegon NV, said a law would give investors more confidence to make long-term decisions on environmentally responsible projects. The move showcases investors’ increased focus on climate change, both as a risk and an opportunity. Quoting the “catastrophic” impact of ignoring the issue, the group said uncontrolled climate change could cost the global economy $23 trillion. “Conversely, greater action on climate change could deliver $26 trillion in global economic benefit by 2030,” the letter, released Friday, said. Most of the 28 EU member states have signed up to an EU-wide pledge to be climate neutral by 2050 but Poland, the Czech Republic and Hungary are dragging their feet. A law would force all member states to achieve climate neutrality by 2050. Ursula von der Leyen, the new president of the European Union’s executive Commission, has made combating climate change one of her top priorities. She has unveiled a “Sustainable Europe Investment Plan” which would support one trillion euros in investment over the next decade, and pledged to turn the 2050 target, something that will require a near-complete phasing-out of fossil fuels, into the “first European Climate Law.”

Output: Omega-3 margarines fail to help in heart study


Input: Consider Input: Teva Pharmaceutical Industries Ltd’s rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx’s lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx’s decision secures easier access to customers for Lilly’s Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen’s Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva’s Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp.  “We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine,” Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. “Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers,” the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva’s drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen’s Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM’s recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York  were down nearly 1 percent at $19.69.

Output: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.


Input: Consider Input: The new paper, published like the first in Proceedings of the National Academy of Sciences, slams the research for “dubious analyses” and “erroneous methodology” and says it “conjured nonexistent effects out of thin air.”  In the 2013 study, researchers had adults answer a 14-item questionnaire meant to sort them into two groups: interested in hedonic well-being (fun and selfish pleasure) or eudaimonic well-being (leading a meaningful life). The two groups, researchers led by psychologist Barbara Frederickson of the University of North Carolina reported, had different patterns of activity in 53 genes. Hedonists had DNA activity akin to people suffering from chronic, illness-inducing stress. Stress-related genes including those involved in inflammation were overactive; genes involved in making antibodies that fight infection were underactive. Hedonists, it seemed, were headed for a disease-ridden existence and an early grave, as media reports warned in stories with headlines like “Meaning is healthier than happiness.”  The claim caught the eye of Nick Brown, a British information technology worker who has become a persistent amateur critic of what he sees as shoddy statistical analysis in psychology research. As he and colleagues scrutinized the 2013 paper, they saw numerous problems, he said. For one thing, the authors failed to rule out that people with specific gene-activity patterns in the immune system might be under the weather when tested. More crucially, Brown said, the happiness questionnaire was flawed. People who scored high on three items meant to identify hedonists scored equally highly on 11 items meant to identify people who seek eudaimonic well-being. “The two constructs are essentially measuring the same thing,” Brown said, so putting people in one category rather than another was “meaningless.”  Most devastating was what happened when Brown grouped the items randomly, calling those who scored high on questions 1, 7  and 8 (or any of 8,191 other combinations) one kind of person and those who scored high on others a second type. Even with such meaningless groupings, there were patterns of gene activity seemingly characteristic of each group. Statistics professor Andrew Gelman of Columbia University, who was not involved in either study, called Brown’s critique “reasonable.”   Flawed statistics have become such a serious problem for journals that many of the world’s top titles are adding extra levels of statistical checks in the peer-review process. Deputy executive editor Daniel Salsbury said PNAS was not changing its longstanding practice, which is “to work within our review process to ensure the work is sound in all aspects.”   In a reply to Brown, Frederickson and coauthor Steven Cole of the University of California, Los Angeles, reject the criticism and say they have replicated their 2013 findings in a new sample of 122 people.


Output: Happiness study draws frowns from critics.